Introduction: Panic disorder (PD) is a common anxiety disorder. Despite neurophysiological advances, its
pathogenesis is still not well elucidated. Although the recommended pharmacological agents have demonstrated efficacy
and a rather acceptable tolerability, yet many patients do not respond fully and still suffer from residual symptoms. There
is a need for new pharmacological classes with better tolerability and efficacy, and faster onset of action. The purpose of
this review is to illustrate the existing non-antidepressant treatment of PD as well as the recent advances in the treatment
Methods: 38 articles discussing pharmacological treatment of PD were selected for this review. They were mainly openlabel
studies, case-reports and review articles.
Results: We reviewed the studies on anticonvulsants, benzodiazepines, gamma amino butyric acid (GABAergic) products,
atypical antipsychotics, clonidine, as well as emerging drugs in the treatment of PD such as metabotropic glutamate II
agonists, and D-cycloserine.
Conclusion: Although most of the drugs tested were proven effective and well tolerated, the studies on the nonconventional
agents are restricted to open-label trials and case reports. Further studies are required to establish their
efficacy and tolerability in the treatment of panic disorder.